MENLO PARK, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that Novogene is using its Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany, serving customers across the European scientific community. Novogene is a leading provider of genomic services and bioinformatics expertise, working with a wide range of leading research institutions, clinical and commerc ...

MENLO PARK, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that Novogene is using its Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany, serving customers across the European scientific community. Novogene is a leading provider of genomic services and bioinformatics expertise, working with a wide range of leading research institutions, clinical and commerc ...

MENLO PARK, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Wednesday, August 7, 2024, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349 ...

MENLO PARK, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/. Date: Wednesday, August 7, 2024, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-34 ...

文章核心观点 - 公司PacBio与Form Bio合作,共同成立AAV工作组,旨在推动AAV行业的标准化和协作 [1][2][3][4] - PacBio拥有HiFi长读长测序和SBB短读长测序两大核心技术,正在不断拓展其基因组解决方案 [5][6][7] - 长读长测序市场预计未来将保持30.92%的高速增长,受益于遗传疾病和个性化医疗的需求增加 [8][9] - PacBio近期推出了针对神经系统疾病的重复扩张基因检测产品,以及适用于多种样本类型的DNA提取试剂盒 [10][11] - 受整体市场环境影响,PacBio股价在过去6个月内大幅下跌86% [12] 行业概况 - 长读长测序市场规模在2022年达到4.551亿美元,预计未来将以30.92%的年复合增长率快速增长 [8] - 市场增长的主要驱动因素包括遗传疾病和染色体紊乱的高发病率、个性化医疗的兴起,以及新技术的不断涌现 [9] 公司概况 - PacBio是一家生命科学技术公司,专注于开发先进的基因测序解决方案 [5] - 公司拥有HiFi长读长和SBB短读长两大核心技术,正在不断推出新产品和技术 [5][6][7] - 近期推出了针对神经系统疾病的重复扩张基因检测产品,以及适用于多种样本类型的DNA提取试剂盒 [10][11] - 受整体市场环境影响,公司股价在过去6个月内大幅下跌86% [12] 同行业公司表现 - DaVita、Ecolab和Universal Health Services等同行业公司近期业绩表现良好 [14][15][16][17] - DaVita和Ecolab的股价在过去一年内分别上涨44%和33.8%,优于行业整体水平 [15][16] - Universal Health Services的每股收益增长率预计将达到30.5% [17]

Pacific Biosciences of California (PACB) closed the latest trading day at $1.37, indicating a +0.74% change from the previous session's end. This move outpaced the S&P 500's daily loss of 0.41%. Elsewhere, the Dow saw a downswing of 0.12%, while the tech-heavy Nasdaq depreciated by 0.71%.Prior to today's trading, shares of the maker of genetic analysis technology had lost 29.9% over the past month. This has lagged the Medical sector's gain of 1.74% and the S&P 500's gain of 3.53% in that time.The investment ...

Consortium Delivers Publicly Available Datasets that Enrich Detection of Rare and Novel Genetic Variants for Advances in Human Disease ResearchMENLO PARK, Calif., June 10, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the international Consortium for Long-Read Sequencing (CoLoRS), today announced the launch of the first publicly available and free HiFi long-read variant frequency database with global representatio ...

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by a decent first-quarter 2024 performance and its product development activities, is expected to contribute further. However, stiff competition and macroeconomic concerns persist.In the year-to-date period, this Zacks Rank #3 (Hold) stock has lost 80.9% against 6.9% growth of the industry. The S&P 500 Composite also gained 11.6% in the same tim ...

Pacific Biosciences of California (PACB) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this maker of genetic analysis technology have returned +36% over the past month versus the Zacks S&P 500 composite's +6.1% change. The Zacks Medical - Instruments industry, to which Pacific Biosciences belongs, has gained 6.9% over this period. Now the key question i ...

Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center ProgramALISO VIEJO, Calif. and MENLO PARK, Calif., May 15, 2024 /PRNewswire/ --Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies' selection by the University of California, Irvine (UCI) and the GREGoR Consortium (Genomi ...